White House’s Navarro says pharma tariffs likely under Section 232 probe
by Reuters Aug 14, 2025
White House trade adviser Peter Navarro said on Thursday that the Trump administration is likely to levy tariffs on pharmaceutical imports under a "Section 232" trade investigation because it's "very clear that we have a national security crisis" due to U.S. reliance on foreign producers in the sector.
In an televised interview with CNBC, Navarro did not provide any details on the timing of the Section 232 probe.
He said that President Donald Trump's executive order to shore up supply chains will provide price floors for domestic producers of drug ingredients through long-term strategic contracts that will ensure sufficient demand. At the same time, tariffs will deter dumping of pharma precursors from India and China, he added.
Reuters
Similar Stories
Berlin and UkraineInvest establish first U.S. partner office to expand American investment in Ukraine
View ArticleUS, Australia sign Customs Mutual Assistance Agreement
CMAA enhances trade and security cooperation
View Article
‘China Shock 2.0’: EU primed for action?
View ArticleAfreximbank Africa Trade Report shows Africa can turn geopolitical disruptions into long-term growth opportunity
The report highlights Africa’s continued growth resilience despite significant headwinds occasioned by escalating geopolitical tensions and ensuing economic shifts
View Article
Strait of Hormuz tensions highlight need to put seafarer welfare at the center of contingency planning, says AVS Global Ship Supply
View ArticleFreight forwarders helped make Brexit-era UK–EU trade manageable
As the UK marks ten years since the Brexit referendum, the British International Freight Association (BIFA) is highlighting the vital role played by its members in helping businesses adapt to…
View ArticleGet the most up-to-date trending news!
SubscribeIndustry updates and weekly newsletter direct to your inbox!
Follow us on social media:
